Caliway Biopharmaceuticals (6919.TW)

Executive Summary

Caliway Biopharmaceuticals is a Taiwan-based clinical-stage biotechnology company developing novel small-molecule therapies for non-invasive aesthetic and medical applications. Its lead candidate, CBL-514, targets localized fat reduction and lipoma treatment, addressing a large and growing market in aesthetic medicine and rare diseases. The company has completed multiple Phase 2 trials demonstrating safety and efficacy in subcutaneous fat reduction and cellulite, with encouraging results that support advancement into late-stage development. In September 2025, Caliway initiated a Phase 3 trial (NCT07140939) for subcutaneous fat reduction, recruiting approximately 200 patients with an expected completion date of September 2026. Additionally, a Phase 2 trial for Dercum's disease, a painful lipoma condition, is ongoing and expected to complete in April 2026. With a strong pipeline, positive early data, and a clear regulatory pathway, Caliway is positioned to capture significant value in the aesthetics and rare disease markets. However, as a small-cap public company, it faces execution risks and dependence on clinical trial outcomes.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Topline Data for CBL-514 in Subcutaneous Fat Reduction70% success
• Q3 2026Phase 2 Topline Data for CBL-514 in Dercum's Disease60% success
• Q4 2026Potential Partnership or Licensing Deal for CBL-514 in Aesthetic Indications40% success